BlossomHill Therapeutics, Inc. priced its initial public offering at $16.00 a share, offering 9,375,000 shares of common stock, to list on the Nasdaq Global Select Market under the symbol BLSM. It filed a Form S-1 registration statement for an initial public offering on July 17, 2026. As of November 6, 2026, its final prospectus is on file (Form 424B4, August 7, 2026).
Sell to companies like BlossomHill Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
BlossomHill Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-17. It has amended it 1 time. It filed its final prospectus on 2026-08-07, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for BlossomHill Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 18, 2026 | Stake report, Schedule 13D, by ORBIMED ADVISORS LLC | 8.9% of the class | 5%+ stakes | Source |
| August 17, 2026 | Stake report, Schedule 13G, by Vivo Innovation Fund II Holdings, L.P. | 5.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Perceptive Advisors LLC | 5.9% of the class | 5%+ stakes | Source |
| August 13, 2026 | Stake report, Schedule 13D, by Cormorant Asset Management, LP | 11.8% of the class | 5%+ stakes | Source |
| December 10, 2025 | Form D, private offering | $84.15M sold | Form D page | Source |
Check before you invest in BlossomHill Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on BlossomHill Therapeutics, Inc. and the records around it.
The people at BlossomHill Therapeutics, Inc.
- CARL GORDON is also named on 1 other Form D filing: Avenzo Therapeutics, Inc. (Sep 2025)
BlossomHill Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- Cormorant Global Healthcare Master Fund, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
- Perceptive Advisors LLC also filed stake reports on 57 other companies: Nautilus Biotechnology, Inc. (Nov 2026), Athira Pharma, Inc. (Oct 2026), IRulya Therapeutics Inc. (Oct 2026)
Also filing to list on the Nasdaq Global Select Market
IPO filings on the Nasdaq Global Select Market in Q3 2026, newest first.
- HMH Holding Inc (Sep 2026)
- SB Energy, Inc. (Sep 2026)
- Gloo Holdings, Inc. (Jul 2026)
Watch BlossomHill Therapeutics, Inc.
Get an email when BlossomHill Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BlossomHill Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on BlossomHill Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BlossomHill Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Select Market under the symbol “BLSM.”From the 424B4 filed 2026-08-07
Shares offered
This is an initial public offering of shares of common stock of BlossomHill Therapeutics, Inc. We are offering 9,375,000 shares of our common stock to be sold in this offering.From the 424B4 filed 2026-08-07
Offering price
The initial public offering price is $16.00 per share.From the 424B4 filed 2026-08-07
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, (i) to advance the clinical development of BH-30643 in EGFR-mutant NSCLC, including continuation of our ongoing global Phase 1/2 clinical trial and the planned initiation of a potential registrational Phase 2 clinical trial, (ii) to advance the clinical development of BH-30236, including continuation of our ongoing Phase 1 clinical trial of BH-30236 as both a monotherapy and combination therapy in AML, HR-MDS and other hematological malignancies, (iii) to complete IND-enabling studies, submit an IND and initiate a Phase 1 clinical trial of BH-501284, and (iv) the remainder for other…From the 424B4 filed 2026-08-07
Net loss or income
For the years ended December 31, 2024 and 2025, our net losses were approximately $30.7 million and $60.6 million,From the S-1/A filed 2026-08-03
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-07-17 | Registration statement filed | S-1 |
| 2026-08-03 | Registration statement amended | S-1/A |
| 2026-08-07 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for BlossomHill Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.